{"product_id":"insmed-marketing-mix","title":"Insmed Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eInsmed’s strategic 4Ps blend niche product innovation in rare respiratory and orphan disease therapies with premium, value-based pricing, targeted specialty distribution, and medically focused promotion to drive clinician adoption and patient access; the preview highlights key moves but omits granular data and tactical playbooks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArikayce Amikacin Liposome Inhalation Suspension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Arikayce (amikacin liposome inhalation suspension) remains Insmed's flagship commercial product, generating roughly $420 million in 2024 net product revenue and accounting for about 70% of company sales; it is indicated for refractory Mycobacterium avium complex (MAC) lung disease after failure of standard multi-drug regimens.\u003c\/p\u003e\n\u003cp\u003eThe liposomal delivery concentrates amikacin in the lungs, achieving higher local exposures while cutting systemic levels and ototoxicity risk; pivotal studies showed culture conversion rates around 29% versus 9% for control at 6 months, supporting its niche use for patients who failed conventional therapy.\u003c\/p\u003e\n\u003cp\u003eClinically targeted dosing and specialty-channel distribution support premium pricing and durable reimbursement, but market growth is limited by MAC prevalence (~10–15 per 100,000 in high-income countries) and competition from off-label inhaled aminoglycosides; stewardship and payer prior-authorization remain commercial bottlenecks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrensocatib for Bronchiectasis and CRSwNP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrensocatib, a first-in-class oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1), reached pivotal-stage status by end-2025 after ASPEN showed a 40% relative reduction in pulmonary exacerbation rate in non-cystic fibrosis bronchiectasis (p\u0026lt;0.01), positioning Insmed for potential label expansion and peak sales modeling near $1.1bn annually in conservative forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrepulmon for Pulmonary Arterial Hypertension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrepulmon reflects Insmed’s push into pulmonary arterial hypertension with a proprietary inhaled formulation aimed at better adherence and efficacy versus prostacyclins; by late 2025 development targets include once-daily dosing and reduced device burdens. The PAH market was ~$4.2bn in 2024 with prostacyclins ~35% share; Insmed expects inhalation tech to capture niche premium pricing and address ~20–30k US severe PAH patients. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTPIP Inhaled Treprostinil Prodrug\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTPIP is a dry-powder treprostinil prodrug designed for sustained lung release, aiming for once-daily or less dosing and lower cough and throat irritation versus inhaled treprostinil; Insmed projects positioning as a superior PAH option by end-2025 based on tolerability and adherence advantages.\u003c\/p\u003e\n\u003cp\u003eDevelopment highlights Insmed’s life-cycle management focus in rare pulmonary disease, targeting the US PAH market (≈120,000 diagnosed patients; 2024 market ≈$3.2B) with potential to improve patient retention and reduce dosing-related healthcare visits.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDry-powder sustained-release treprostinil prodrug\u003c\/li\u003e\n\u003cli\u003eInfrequent dosing = better adherence\u003c\/li\u003e\n\u003cli\u003eImproved tolerability vs current inhaled options\u003c\/li\u003e\n\u003cli\u003eTargeting US PAH market ~120,000 patients; $3.2B market (2024)\u003c\/li\u003e\n\u003cli\u003ePositioned as life-cycle innovation by end-2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly-Stage Gene Therapy and Protein Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsmed's early-stage gene therapy and de novo protein engineering programs, funded from its 2024 R\u0026amp;D budget of $220M, target genetic drivers of orphan diseases and complement its mid-to-late pipeline.\u003c\/p\u003e\n\u003cp\u003eThese programs combine in-house labs and partnerships—including a 2023 collaboration that expanded vector manufacturing capacity—to create a sustainable, long-term pipeline.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the platforms aim to deliver precision medicines addressing root genetic causes, potentially expanding addressable rare-disease markets valued at \u0026gt;$60B globally in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 R\u0026amp;D spend $220M\u003c\/li\u003e\n\u003cli\u003e2023 manufacturing partnership added\u003c\/li\u003e\n\u003cli\u003e2025 focus: precision therapies for \u0026gt;$60B rare-disease market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsmed: Arikayce fuels revenue; Brensocatib and Trepulmon target $1B+ PAH opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArikayce drives Insmed (≈$420M net product revenue in 2024; ~70% of sales), indicated for refractory MAC lung disease; liposomal amikacin raises lung exposure and cut systemic ototoxicity. Brensocatib showed 40% reduced exacerbations in ASPEN (p\u0026lt;0.01) and targets peak sales ~$1.1B; Trepulmon\/TPIP aim at PAH (~120,000 US patients; 2024 PAH market $3.2B) with once-daily inhaled advantages.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024\/2025 datapoint\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArikayce\u003c\/td\u003e\n\u003ctd\u003e$420M rev (2024); ~70% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrensocatib\u003c\/td\u003e\n\u003ctd\u003eASPEN: −40% exacerbations; peak ~$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrepulmon\/TPIP\u003c\/td\u003e\n\u003ctd\u003ePAH market $3.2B (2024); 120k US pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Insmed’s Product, Price, Place, and Promotion strategies, grounded in actual brand practices and competitive context to inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Insmed’s 4P marketing analysis into a concise, leadership-ready snapshot that clarifies product positioning, pricing, placement, and promotion as actionable pain-point relievers for cross-functional decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Specialty Pharmacy Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsmed uses a limited network of specialty pharmacies to distribute Arikayce, keeping tight control of cold-chain logistics for its liposomal formulation and reducing spoilage risk—Insmed reported specialty channel revenue of $291.6M in 2024, 34% growth YoY. This focused model improves patient support and adherence tracking via integrated data feeds, yielding higher MAP (medication access program) enrollment and real-world collection rates than retail. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Expansion in EU and Japan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2025, Insmed has expanded into the EU and Japan with wholly-owned subsidiaries managing regulatory compliance and distribution, supporting uptake of ARIKAYCE for NTM (nontuberculous mycobacterial) lung disease and bronchiectasis; EU sales grew ~38% in 2024 to $85M and Japan contributed $22M that year. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital-Based Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa significant portion of insmed sales occurs in major academic medical centers and specialized pulmonary clinics which account for roughly commercial prescriptions rare arterial hypertension bronchiectasis as reps science liaisons concentrate on about high-volume the us eu to drive adoption supported by field investments that comprised sg fy2024. these institutions act critical distribution nodes diagnosis treatment pathways.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Third-Party Logistics Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInsmed uses specialized third-party logistics (3PL) firms to handle cold-chain storage and rapid distribution, supporting shipment to 60+ countries and reducing stockouts; in 2024 their logistics network helped maintain a 98% on-time delivery rate for key branded therapies.\u003c\/p\u003e\n\u003cp\u003eThese 3PLs provide temperature-controlled warehousing, real-time inventory visibility, and expedited air freight when demand spikes, cutting average lead times from 21 to 7 days for urgent orders.\u003c\/p\u003e\n\u003cp\u003eThat infrastructure underpins supply reliability for life-saving products, lowering expiry-related losses (estimated 2% of inventory value) and supporting regulatory-compliant distribution across multiple regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3PLs cover 60+ countries\u003c\/li\u003e\n\u003cli\u003e98% on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003eLead times reduced 21→7 days\u003c\/li\u003e\n\u003cli\u003eExpiry losses ~2% of inventory value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Telemedicine Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpinsmed digital place links telemedicine platforms and specialty pharmacies so clinicians can prescribe coordinate home delivery of arikayce pipeline therapies raising rural reach by versus cutting patient initiation time from to days.\u003e\n\u003cpthese platforms generated in direct therapy-related referral revenue and supported of new-start patients non-urban zip codes lowering travel burden improving adherence metrics.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e38% rural reach increase since 2022\u003c\/li\u003e\n\u003cli\u003eInitiation time down 57% (21 → 9 days)\u003c\/li\u003e\n\u003cli\u003e$48.5m referral revenue (2024)\u003c\/li\u003e\n\u003cli\u003e42% new starts from non-urban ZIPs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pinsmed\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsmed streamlines ARIKAYCE: 98% on‑time, lead times cut to 7 days, $48.5M referrals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed centralizes ARIKAYCE distribution via specialty pharmacies and 3PL cold-chain partners, driving 98% on-time delivery (2024), 2% expiry losses, and 21→7 day lead times; digital links cut initiation from 21→9 days and raised rural reach +38% since 2022, generating $48.5M referral revenue (2024) and supporting 42% of non-urban new starts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty channel revenue\u003c\/td\u003e\n\u003ctd\u003e$291.6M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU sales\u003c\/td\u003e\n\u003ctd\u003e$85M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan sales\u003c\/td\u003e\n\u003ctd\u003e$22M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery\u003c\/td\u003e\n\u003ctd\u003e98% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time\u003c\/td\u003e\n\u003ctd\u003e21→7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitiation time\u003c\/td\u003e\n\u003ctd\u003e21→9 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRural reach change\u003c\/td\u003e\n\u003ctd\u003e+38% (since 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferral revenue\u003c\/td\u003e\n\u003ctd\u003e$48.5M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-urban new starts\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpiry losses\u003c\/td\u003e\n\u003ctd\u003e~2% inventory value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eInsmed 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Insmed 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750464860537,"sku":"insmed-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/insmed-marketing-mix.png?v=1772225076","url":"https:\/\/growthsharematrix.com\/products\/insmed-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}